Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders.

Curemark’s pipeline includes preclinical and clinical-stage programs for the treatment of Autism, ADHD, addiction, Schizophrenia and Parkinson’s. This disruption is at the core of Curemark’s vision.

As the longstanding agency of record for Curemark, RPR helped to develop the company’s brand messaging and expansion into being recognized as a revolutionary biopharmaceutical company. RPR generated sustained media coverage to drive awareness of the company’s research, treatments and activities among target audiences such as doctors and health practitioners who treat autism, ADHD, Schizophrenia, and Parkinson’s Disease, potential investors, the science community, and families of patients, support groups, and charities. 

Additionally, RPR secured extensive broadcast coverage for Curemark on NY1, NBC, Fox News, ABC Channel 8, KEYC News12, KFS12, KHQQ6, KLTV, KMOV, KSWO, KTVN, KUAM, KVUU, KWTV, KXNET, NewsWest9, Seattle Pi, WAFF, WDRB, WFXG, WICU, WIS, WKOW, WLOX, WOIO, WSFA, WTHR, WTOL, WTVM, as well as coverage in print and digital outlets, such as Fast Company, Church Leader Tonight, Sunday Star Ledgar, Huffington Post, Bloomberg, Entrepreneur, Leaders, and Device Daily.